Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence

References

• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculation2002106253143 342112485966
   PubMed Web of Science ®Google Scholar
• AustinMAKingMCVranizanKMKraussRMAtherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease riskCirculation1990822495 5062372896
   PubMed Web of Science ®Google Scholar
• Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors CollaborationTriglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studiesLancet201037597261634 163920452521
   PubMed Web of Science ®Google Scholar
• LiCFordESTsaiJZhaoGBalluzLSGiddingSSSerum non-high-density lipoprotein cholesterol concentration and risk of death from cardiovascular diseases among US adults with diagnosed diabetes: the Third National Health and Nutrition Examination Survey linked mortality studyCardiovasc Diabetol2011104621605423
   PubMed Web of Science ®Google Scholar
• KathiresanSOtvosJDSullivanLMIncreased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart StudyCirculation2006113120 2916380547
   PubMed Web of Science ®Google Scholar
• ManoriaPCChopraHKParasharSKThe nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategiesIndian Heart J2013656683 69024407538
   PubMedGoogle Scholar
• Toft-PetersenAP1TilstedHHAarøeJSmall dense LDL particles – a predictor of coronary artery disease evaluated by invasive and CT-based techniques: a case-control studyLipids Health Dis2011102121262005
   PubMed Web of Science ®Google Scholar
• ColhounHMBetteridgeDJDurringtonPNPrimary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialLancet20043649435685 69615325833
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo controlled trialLancet20033612005 201612814710
   PubMed Web of Science ®Google Scholar
• JunMZhuBTonelliMEffects of fibrates in kidney disease: a systematic review and meta-analysisJ Am Coll Cardiol201260202061 207123083786
   PubMed Web of Science ®Google Scholar
• CollinsAJKasiskeBHerzogCExcerpts from the United States Renal Data System 2006 Annual Data ReportAm J Kidney Dis2007491 Suppl 1A6 A7S1 S29617189040
   PubMedGoogle Scholar
• GrahamDJStaffaJAShatinDIncidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugsJAMA2004292212585 259015572716
   PubMed Web of Science ®Google Scholar
• PreissDTikkanenMJWelshPLipid-modifying therapies and risk of pancreatitis: a meta-analysisJAMA20123088804 81122910758
   PubMed Web of Science ®Google Scholar
• Lofibra (Micronized fenofibrate) [prescribing information]North Wales, PA, USATeva Pharmaceuticals2010
   Google Scholar
• AIM-HIGH InvestigatorsNiacin in patients with low HDL cholesterol levels receiving intensive statin therapyN Engl J Med2011365242255 226722085343
   PubMed Web of Science ®Google Scholar
• HPS2-THRIVE Collaborative GroupHPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatmentEur Heart J201334171279 129123444397
   PubMed Web of Science ®Google Scholar
• YokoyamaMOrigasaHMatsuzakiMEffects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysisLancet200736995671090 109817398308
   PubMed Web of Science ®Google Scholar
• ScottRO’BrienRFulcherGEffects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) StudyDiabetes Care2009323493 49818984774
   PubMed Web of Science ®Google Scholar
• ACCORD Study GroupGinsbergHNElamMBLovatoLCEffects of combination lipid therapy in type 2 diabetes mellitusN Engl J Med2010362171563 156420228404
   PubMed Web of Science ®Google Scholar
• TenenbaumAFismanEZFibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reductionCardiovasc Diabetol20121112523057687
   PubMed Web of Science ®Google Scholar
• CatapanoALReinerZDe BackerGESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)Eur Heart J201132141769 181821712404
   PubMed Web of Science ®Google Scholar
• StaelsBFruchartJCTherapeutic roles of peroxisome proliferator-activated receptor agonistsDiabetes20055482460 247016046315
   PubMed Web of Science ®Google Scholar
• BalakumarPRoseMGantiSSKrishanPSinghMPPAR dual agonists: are they opening Pandora’s Box?Pharmacol Res200756291 9817428674
   PubMed Web of Science ®Google Scholar
• Lipaglyn (Saroglitazar) [prescribing information]Ahmedabad, IndiaCadila Healthcare2013
   Google Scholar
• JaniRHKansagraKJainMRPatelHPharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjectsClin Drug Investig20133311809 816
   PubMed Web of Science ®Google Scholar
• PaiVPaneerselvamAMukhopadhyaySA multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V)J Diabetes Sci Technol201481132 14124876549
   PubMedGoogle Scholar
• JaniRHPaiVJhaPA multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI)Diabetes Technol Ther201416263 7124138536
   PubMed Web of Science ®Google Scholar